Product information

From Health Canada

New search

Current status:

Cancelled Post Market

Current status date:

2019-01-03

Original market date: ^{See footnote 1}

2010-05-26

Lot number: ^{See footnote 2}

AV1017

Expiry date: ^{See footnote 2}

2020-02-29

Product name:

HIGH PROTECTION EMULSION

DIN:

02351811 Electronic product monograph is not available

Company:

PIERRE FABRE DERMO-COSMETIQUE CANADA INC
115 9955 Rue De Chateauneuf
Brossard
Quebec
Canada J4Z 3V5

Class:

Human

Dosage form(s):

Emulsion

Route(s) of administration:

Topical

Number of active ingredient(s):

Schedule(s):

OTC

American Hospital Formulary Service (AHFS): ^{See footnote 3}

84:80.00

Anatomical Therapeutic Chemical (ATC): ^{See footnote 4}

D02BA30 COMBINATIONS OF PROTECTIVES AGAINST UV-RADIATION

Active ingredient group (AIG) number:^{See footnote5}

0352739002

List of active ingredient(s)
Active ingredient(s)	Strength
BEMOTRIZINOL	4.5 % / W/W
BISOCTRIZOLE	6.0 % / W/W
OCTINOXATE	7.5 % / W/W

New search

Same active ingredient group number

Footnotes

Footnote 1

The earliest marketed date recorded in the Drug Product Database.

Return to footnote 1referrer

Footnote 2

When a manufacturer decides to discontinue the sale of their drug, the date of discontinuation is the date of the last sale by the manufacturer. The DIN will be cancelled further to the receipt of a sale discontinuation notification from the manufacturer. The status of the DIN will be updated to “Cancelled (Post-Market)” in the online Drug Product Database. For DINs cancelled on or after March 14, 2017, the latest expiry date and lot number of the product distributed in Canada will be posted on the online Drug Product Database. Other parties in the health product distribution chain such as wholesalers, retailers, pharmacists and medical practitioners may still sell or distribute that drug after DIN cancellation if the expiry date of the drug lot has not passed. This may be acceptable so long as the DIN cancellation is not due to health and/or safety reasons.

Return to footnote 2referrer

Footnote 3

The American Hospital Formulary Service permits an easy review of information on a group of drugs with similar activities and uses and allows the reader to determine quickly the similarities and differences among drugs within a group. AHFS® Pharmacologic/Therapeutic Classification© used with permission. © 2022, the American Society of Health-System Pharmacists, Inc. (ASHP). The Data is a part of the AHFS Drug Information®; ASHP is not responsible for the accuracy of transpositions from the original context.

Return to footnote 3referrer

Footnote 4

The purpose of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system is to be used as a tool for drug utilization research in order to improve quality of drug use. Drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutical properties.

Return to footnote 4referrer

Footnote 5

The AIG number is a 10 digit number that identifies products that have the same active ingredient(s) and ingredient strength(s). The AIG is comprised of three portions:

the first portion (2 digits) identifies the number of active ingredients,
the second portion (5 digits) identifies the unique groups of active ingredients(s),
the last portion (3 digits) identifies the active ingredient group strength. The strength group has a tolerance of ‑2% to +10%.

Return to footnote 5referrer

Application information

Related information

Contact us

Version 4.0.2

Report a problem or mistake on this page

Report a problem on this page

Date modified:: 2019-03-01